相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Efficacy and Tolerability of Calcitonin Gene-Related Peptide-Targeted Monoclonal Antibody Medications as Add-on Therapy to OnabotulinumtoxinA in Patients with Chronic Migraine
Fred Cohen et al.
PAIN MEDICINE (2021)
Real-World Evidence for Control of Chronic Migraine Patients Receiving CGRP Monoclonal Antibody Therapy Added to OnabotulinumtoxinA: A Retrospective Chart Review
Andrew M. Blumenfeld et al.
PAIN AND THERAPY (2021)
Erenumab and OnabotulinumtoxinA Combination Therapy for the Prevention of Intractable Chronic Migraine without Aura: A Retrospective Analysis
Mark Armanious et al.
JOURNAL OF PAIN & PALLIATIVE CARE PHARMACOTHERAPY (2021)
Eptinezumab in episodic migraine: A randomized, double-blind, placebo-controlled study (PROMISE-1)
Messoud Ashina et al.
CEPHALALGIA (2020)
Dual Therapy With Anti-CGRP Monoclonal Antibodies and Botulinum Toxin for Migraine Prevention: Is There a Rationale?
Lanfranco Pellesi et al.
HEADACHE (2020)
From transformation to chronification of migraine: pathophysiological and clinical aspects
M. Torres-Ferrus et al.
JOURNAL OF HEADACHE AND PAIN (2020)
Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2
Richard B. Lipton et al.
NEUROLOGY (2020)
The Effect of Adding Calcitonin Gene-Related Peptide Monoclonal Antibodies to Onabotulinum Toxin A Therapy on Headache Burden: A Retrospective Observational Case Series
Seniha N. Ozudogru et al.
HEADACHE (2020)
Mechanism of Action of OnabotulinumtoxinA in Chronic Migraine: A Narrative Review
Rami Burstein et al.
HEADACHE (2020)
An open-label prospective study of the real-life use of onabotulinumtoxinA for the treatment of chronic migraine: the REPOSE study
Fayyaz Ahmed et al.
JOURNAL OF HEADACHE AND PAIN (2019)
Botulinum Neurotoxin Light Chains Expressed by Defective Herpes Simplex Virus Type-1 Vectors Cleave SNARE Proteins and Inhibit CGRP Release in Rat Sensory Neurons
Charles Joussain et al.
TOXINS (2019)
The American Headache Society's Position Statement on Integrating New Migraine Treatments into Clinical Practice - Comments
James A. Charles et al.
HEADACHE (2019)
Exploring the effects of extracranial injections of botulinum toxin type A on prolonged intracranial meningeal nociceptors responses to cortical spreading depression in female rats
Agustin Melo-Carrillo et al.
CEPHALALGIA (2019)
FORWARD Study: Evaluating the Comparative Effectiveness of OnabotulinumtoxinA and Topiramate for Headache Prevention in Adults With Chronic Migraine
John F. Rothrock et al.
HEADACHE (2019)
Life With Migraine: Effects on Relationships, Career, and Finances From the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study
Dawn C. Buse et al.
HEADACHE (2019)
Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition
Jes Olesen
CEPHALALGIA (2018)
Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine A Randomized Clinical Trial
David W. Dodick et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2018)
Long-term study of the efficacy and safety of OnabotulinumtoxinA for the prevention of chronic migraine: COMPEL study
Andrew M. Blumenfeld et al.
JOURNAL OF HEADACHE AND PAIN (2018)
CGRP as the target of new migraine therapies - successful translation from bench to clinic
Lars Edvinsson et al.
NATURE REVIEWS NEUROLOGY (2018)
Galcanezumab in chronic migraine The randomized, double-blind, placebo-controlled REGAIN study
Holland C. Detke et al.
NEUROLOGY (2018)
Fremanezumab-A Humanized Monoclonal Anti-CGRP Antibody-Inhibits Thinly Myelinated (Aδ) But Not Unmyelinated (C) Meningeal Nociceptors
Agustin Melo-Carrillo et al.
JOURNAL OF NEUROSCIENCE (2017)
Fremanezumab for the Preventive Treatment of Chronic Migraine
Stephen D. Silberstein et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Direct and Indirect Costs of Chronic and Episodic Migraine in the United States: A Web-Based Survey
Andrew Messali et al.
HEADACHE (2016)
Best Practices for Patients With Chronic Migraine: Burden, Diagnosis, and Management in Primary Care
Amaal J. Starling et al.
MAYO CLINIC PROCEEDINGS (2015)
OnabotulinumtoxinA decreases interictal CGRP plasma levels in patients with chronic migraine
Eva Cernuda-Morollon et al.
PAIN (2015)
The diagnosis and treatment of chronic migraine
Mark W. Weatherall
THERAPEUTIC ADVANCES IN CHRONIC DISEASE (2015)
Chronic migraine
Todd J. Schwedt
BMJ-BRITISH MEDICAL JOURNAL (2014)
Headache-related health resource utilisation in chronic and episodic migraine across six countries
Joanna C. Sanderson et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2013)
Cost of healthcare for patients with migraine in five European countries: results from the International Burden of Migraine Study (IBMS)
L. M. Bloudek et al.
JOURNAL OF HEADACHE AND PAIN (2012)
Validation of the Headache Impact Test (HIT-6™) across episodic and chronic migraine
Min Yang et al.
CEPHALALGIA (2011)
Quality of life impairment, disability and economic burden associated with chronic daily headache, focusing on chronic migraine with or without medication overuse: A systematic review
Michel Lanteri-Minet et al.
CEPHALALGIA (2011)
Global prevalence of chronic migraine: A systematic review
J. L. Natoli et al.
CEPHALALGIA (2010)
OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial
S. K. Aurora et al.
CEPHALALGIA (2010)
OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial
H. C. Diener et al.
CEPHALALGIA (2010)
Development and testing of the Migraine Disability Assessment (MIDAS) Questionnaire to assess headache-related disability
WF Stewart et al.
NEUROLOGY (2001)
分享论文
